ACHP calls on Congress to increase access to biosimilars by redefining interchangeability requirements and addressing outdated regulations, skewed incentives and PBM practices that intentionally slow their adoption.
ACHP released a statement on the most-favored-nation prescription drug pricing executive order.
ACHP released a statement on drug pricing.
ACHP calls on Congress to curb direct-to-consumer (DTC) drug ad dominance. Patients should be able to access affordable, necessary medications, rather than being swayed by misleading marketing tactics.
ACHP President and CEO Ceci Connolly released a statement in response to CMS’ final CY2026 Medicare Advantage and Part D rule.
